

19



LATVIJAS REPUBLIKAS
PATENTU VALDE

11 LV 12492 B

51 Int.cl. 7 A61K31/425
C07D277/58

Latvijas patents uz izgudrojumu
1995.g. 30.marta Latvijas Republikas likums

12

Īsziņas

21 Pieteikuma numurs: P-99-170

22 Pieteikuma datums: 01.12.1999

41 Pieteikuma publikācijas datums: 20.06.2000

45 Patenta publikācijas datums: 20.01.2001

30 Prioritāte:

852,447	07.05.1997	US
887,810	03.07.1997	US
887,809	03.07.1997	US

86 PCT pieteikums:
PCT/US98/09229, 06.05.1998

87 PCT publikācija:
WO 98/50035, 12.11.1998

73 Īpašnieks(i):

ROMARK LABORATORIES, L.C.; Suite 870,
6200 Courtney Campbell Causeway, Tampa FL
33607, US

72 Izgudrotājs(i):


Jean-Francois ROSSIGNOL (US)

74 Pilnvarotais vai pārstāvis:

Vladimirs ANOHINS, Aģentūra 'TRIA ROBIT';
Aizkraukles iela 23, Rīga LV-1006, LV


54 Virsraksts: Tizoksanīda un nitazoksanīda farmaceitiskas kompozīcijas

57 Kopsavilkums: Farmaceitiska kompozīcija kā aktīvo komponentu satur vai nu savienojumu ar formulu (I)




vai abus kopā. Vislabākā aktīvā komponenta forma ir cietas daļiņas ar izmēru, mazāku par 200 mikroniem un ar vidējo daļiņu lielumu lielāku par 10 mikroniem. Kompozīciju vēlam stabilizēt ar vismaz vienu farmaceitiski saderīgu skābi. Šo kompozīciju var izmantot nosacīti patogēnu infekciju ārstēšanai cilvēkiem ar novājinātu imūno sistēmu un trematožu infekcijas ārstēšanai.

vai savienojumu ar formulu (II),




IZGUDROJUMA FORMULA

1. Farmaceutiska kompozīcija orālai ievadīšanai, kas satur kā aktīvu komponentu vismaz vienu savienojumu, kuru izvēlas no savienojuma ar formulu (I)




un savienojuma ar formulu (II)




2. Kompozīcija saskaņā ar 1. punktu, kas atšķiras ar to, ka aktīvais komponents ir aktīvu daļiņu formā ar daļiņu lielumu mazāku par 200 μm un vidējo daļiņu lielumu lielāku par 10 μm.
3. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka šo aktīvu daļiņu vidējais lielums ir 10-100 μm.
4. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka šo aktīvu daļiņu vidējais lielums ir 20-50 μm.
5. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka mazāk par 10% (masas) šīm aktīvām daļiņām ir daļiņas lielums lielāks par 100 μm.
6. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka vismaz 50% (masas) šīm aktīvām daļiņām ir daļiņas lielums mazāks par 50 μm.
7. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka mazāk par 10% (masas) šīm aktīvām daļiņām ir daļiņas lielums mazāks par 5 μm.

8. Kompozīcija saskaņā ar 2. punktu, kas atšķiras ar to, ka šī kompozīcija satur savienojumu ar formulu (I) un ar formulu (II) aktīvu daļiņu maisījumu, pie kam savienojuma ar formulu (I) masas attiecība pret savienojumu ar formulu (I) un ar formulu (II) procentos ir 0,5-20%.
9. Kompozīcija saskaņā ar 1. punktu, kas atšķiras ar to, ka šī kompozīcija papildus satur vismaz vienu farmaceitiski pieņemamu skābi.
10. Kompozīcija saskaņā ar 9. punktu, kas atšķiras ar to, ka šo farmaceitiski pieņemamu skābi izvēlas no grupas, kura sastāv no citronskābes, glutamīnskābes, dzintarskābes, etānsulfoskābes, etiķskābes, vīnskābes, askorbīnskābes, metānsulfoskābes, fumārskābes, adipīnskābes, ābolskābes un šo skābju maisījumiem.
11. Kompozīcija saskaņā ar 9. punktu, kas atšķiras ar to, ka aktīvais komponents ir cietas vielas formā ar daļiņu ne mazāku par 200 μm un vidējo daļiņu lielumu ne lielāku par 10 μm un kur farmaceitiski pieņemamas skābes masas attiecība pret cietas vielas daļiņām ir 0,01-0,5.
12. Kompozīcija saskaņā ar 11. punktu, kas atšķiras ar to, ka farmaceitiski pieņemamas skābes masas attiecība pret aktīva komponenta cietas vielas daļiņām ir 0,03-0,2.
13. Farmaceutiskas kompozīcijas, kas kā aktīvu komponentu satur vismaz vienu savienojumu, kuru izvēlas no savienojuma ar formulu (I)



un savienojuma ar formulu (II)




pielietojums medikamenta iegūšanā zīdītāju ar pavājinātu imunitāti infekcijas ārstēšanai, ko izraisa mikroorganismi, kurus izvēlas no grupas, kas sastāv no *Cryptosporidium parvum*, *Isospora belli*, *Enterocytozoon bieneusi*, *Encephalitozoon intestinalis*, *Mycobacterium tuberculosis*, *Mycobacterium avium intracellulare*, *Pneumocystis carinii* un *Toxoplasma gondii*.


14. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13 punktu, kas atšķiras ar to, ka aktīvais komponents ir aktīvu daļiņu formā ar vidējo daļiņu lielumu 10-200 μm.
15. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka aktīvais komponents ir daļiņu formā ar vidējo daļiņu lielumu 20-50 μm.
16. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka šī farmaceitiska kompozīcija satur vismaz vienu farmaceitiski pieņemamu skābi.
17. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 16. punktu, kas atšķiras ar to, ka šo farmaceitiski pieņemamu skābi izvēlas no grupas, kura sastāv no citronskābes, glutamīnskābes, dzintarskābes, etānsulfoskābes, etiķskābes, vīnskābes, askorbīnskābes, metānsulfoskābes, fumārskābes, adipīnskābes, ābolskābes un šo skābju maisījumiem.
18. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka aktīvais komponents ir savienojums ar formulu (I).
19. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka aktīvais komponents ir savienojums ar formulu (II).
20. Farmaceitiskas kompozīcijas pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka šis zīdītājs ir cilvēks un kur šo aktīvo komponentu ik dienas ievada 500-2000 mg daudzumā.

21. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 20. punktu, kas atšķiras ar to, ka šo aktīvo komponentu ik dienas ievada 1000-1500 mg daudzumā.

22. Farmaceutiskas kompozīcijas, kas kā aktīvu komponentu satur vismaz vienu savienojumu, kuru izvēlas no savienojuma ar formulu (I)




un savienojuma ar formulu (II)




pielietojums medikamenta iegūšanā trematožu parazītu infekcijas ārstēšanai, kuru izvēlas no grupas, kas sastāv no *Schistosoma Fasciola*, *Fasciolopsis*, *Dicrocoelium*, *Heterophyes* un *Metagonimus*.

23. Farmaceutiskas kompozīcijas, kas kā aktīvu komponentu satur vismaz vienu savienojumu, kuru izvēlas no savienojuma ar formulu (I)



un savienojuma ar formulu (II)




pielietojums medikamenta iegūšanā trematožu parazītu infekcijas ārstēšanai, kuru izvēlas no grupas, kas sastāv no *Schistosoma mansoni*, *Schistosoma haematobium*, *Schistosoma mekongi*, *Schistosoma japonicum*, *Schistosoma intercalatum*, *Fasciola*


hepatica, Fasciola gigantica, Fasciolopsis biski, Dicrocoelium dendriticum, Heterophyes heterophyes un Metagonimus yokogawa.

24. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 23. punktu, kas atšķiras ar to, ka aktīvais komponents ir daļiņu formā ar vidējo daļiņu lielumu 10-200 μm .
25. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 24. punktu, kas atšķiras ar to, ka aktīvais komponents ir daļiņu formā ar vidējo daļiņu lielumu 20-50 μm .
26. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 23. punktu, kas atšķiras ar to, ka šī farmaceutiska kompozīcija satur vismaz vienu farmaceutiski pieņemamu skābi.
27. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 26. punktu, kas atšķiras ar to, ka šo farmaceutiski pieņemamu skābi izvēlas no grupas, kura sastāv no citronskābes, glutamīnskābes, dzintarskābes, etānsulfoskābes, etiķskābes, vīnskābes, askorbīnskābes, metānsulfoskābes, fumārskābes, adipīnskābes, ābolskābes un šo skābju maisījumiem.
28. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 26. punktu, kas atšķiras ar to, ka farmaceutiski pieņemamas skābes masas attiecība pret aktīvām daļiņām ir 0,01-0,5.
29. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 23. punktu, kas atšķiras ar to, ka aktīvais komponents ir savienojums ar formulu (I).
30. Farmaceutiskas kompozīcijas pielietojums saskaņā ar 23. punktu, kas atšķiras ar to, ka aktīvais komponents ir savienojums ar formulu (II).
31. Farmaceutiska pasta topiskai lietošanai, kurā kā aktīvais komponents ietilpst vismaz viena savienojuma, kuru izvēlas no:

savienojuma ar formulu (I)



un savienojuma ar formulu (II)



cietas vielas daļiņas, šo daļiņu lielums mazāks par 200 μm un vidējais daļiņu lielums ir lielāks par 10 μm ;

vismaz viens sabiezinātājs;


vismaz viens mitrinātājs; un

vismaz viena farmaceitiski pieņemama skābe, pie kam pastas pH ir 2-6.


32. Farmaceutiska pasta saskaņā ar 31. punktu, kas atšķiras ar to, ka šī pasta papildus satur vismaz vienu piedevu, kuru izvēlas no grupas, kas sastāv no cetilspirta, glicerīda atvasinājumiem, propilēnglikola un šo savienojumu maisījumiem.

33. Farmaceutiska kompozīcija orālai ievadīšanai, kura satur aktīvo komponentu, šo kompozīciju granulē granulējoša (granulveidojoša) aģenta klātbūtnē, kur šis aktīvais komponents ir vismaz viena savienojuma, kuru izvēlas no:

savienojuma ar formulu (I)



un savienojuma ar formulu (II)



cietas vielas daļiņu formā un kur šīm aktīvām daļiņām lielums mazāks par 200 μm un vidējais daļiņu lielums ir lielāks par 10 μm.

34. Kompozīcija saskaņā ar 33. punktu, kas atšķiras ar to, ka granulējošo (granulveidojošo) aģentu izvēlas no grupas, kas sastāv no polivinilpirolidona, ūdens, spirta, saharozes, hidroksilcelulozes un šo savienojumu maisījumiem.


35. Kompozīcija saskaņā ar 33. punktu, kas atšķiras ar to, ka granulētās aktīvās cietās vielas daļiņas satur vismaz vienu farmaceitiski pieņemamu skābi.

36. Kompozīcija saskaņā ar 35. punktu, kas atšķiras ar to, ka šo farmaceitiski pieņemamu skābi izvēlas no grupas, kura sastāv no citronskābes, glutamīnskābes, dzintarskābes, etānsulfoskābes, etiķskābes, vīnskābes, askorbīnskābes, metānsulfoskābes, fumārskābes, adipīnskābes, ābolskābes un šo skābju maisījumiem.


37. Kompozīcija saskaņā ar 35. punktu, kas atšķiras ar to, ka farmaceitiski pieņemamas skābes masas attiecība pret aktīvo komponentu ir 0,01-0,5.

38. Farmaceutiska kompozīcija orālai ievadīšanai, kura satur aktīvu komponentu, mitrinātāju un cietes atvasinājumu, kur:

šis aktīvais komponents ir vismaz viena savienojuma, kuru izvēlas no:
savienojuma ar formulu (I)



un savienojuma ar formulu (II)




cietas vielas daļiņu formā un kur šo aktīvo daļiņu lielums mazāks par 200 μm un vidējais lielums ir lielāks par 10 μm.

39. Farmaceutiska kompozīcija saskaņā ar 38. punktu, kura papildus satur vismaz vienu farmaceutiski pieņemamu skābi.


40. Farmaceutiska kompozīcija saskaņā ar 38. punktu, kas atšķiras ar to, ka aktīvās daļiņas granulē granulējoša (granulveidojoša) aģenta klātbūtnē, veidojot granulēto aktīvo komponentu, kas satur 2-99,97% (masas) šī aktīva savienojuma un 0,03-10 % (masas) granulējoša (granulveidojoša) aģenta.

41. Farmaceutiska kompozīcija saskaņā ar 40. punktu, kas atšķiras ar to, ka šo granulējošo (granulveidojošo) aģentu izvēlas no grupas, kas sastāv no polivinilpirolidona, ūdens, spirta, saharozes, hidroksilcelulozes un šo savienojumu maisījumiem.

42. Aktīva komponenta šķidra suspensija orālai ievadīšanai, šī suspensija satur: kā aktīvo komponentu vismaz viena savienojuma, kuru izvēlas no:
savienojuma ar formulu (I)



un savienojuma ar formulu (II)



cietas vielas daļiņas; šo daļiņu lielums mazāks par 200 μm un vidējais daļiņu lielums ir lielāks par 10 μm; un vismaz vienu farmaceutiski pieņemamu skābi, pie kam suspensijas pH ir 2-6.

43. Suspensija saskaņā ar 42. punktu, kas atšķiras ar to, ka suspensijas pH ir 3-5.


44. Suspensija saskaņā ar 42. punktu, kura papildus satur granulējošu (granulveidojošu) agentu.

PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE


BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a pharmaceutical composition containing as active agent at least one compound selected among the group consisting of formula (I)



and formula (II)



The active agent is preferably in the form of particles having a particle size smaller than 200 μm and a mean particle size of greater than 10 μm .

The invention also relates to pharmaceutical compositions stabilized with at least one pharmaceutically acceptable acid.

The pharmaceutical compositions are particularly useful for treatment of opportunistic infections in persons with compromised or suppressed immune systems, and in treatment of infections of trematodes.

Description of the Related Art

There is an urgent need for the development of methods for treatment of a number of parasitic and bacterial infections in humans with compromised immune systems (AIDS, cancer patients, elderly, aging, organ transplant patients on immunosuppressive drugs). Another area of concern is trematode infections, particularly in tropical climates. There is thus a need for a pharmaceutical composition which can be tolerated by even immunocompromised humans, and which is storage stable even in tropical environments.

More specifically, *Toxoplasma gondii* is a protozoan and is among the most prevalent causes of latent infection of the central nervous system throughout the world. Many healthy people are infected with the parasite, but usually the immune system keeps the organism under control. *T. gondii* is the most common opportunistic pathogen of the brain in AIDS patients. At present, toxoplasmosis is becoming an increasing problem not only because of AIDS, but also because of wider use of immunosuppressive drugs (e.g., as administered to organ-transplant

patients). Toxoplasmosis is usually treated with a combination of pyrimethamine and sulfadiazine. While the drugs are effective, they do not kill cysts of the parasite, so the treatment must be continued as a maintenance dose. Toxicity often forces discontinuation of the drug, particularly in the immunosuppressed, and relapses result. The statistics are not good, with reported death rates of about 70 percent in immunodeficient patients and median survival of four months.

Cryptosporidiosis is caused by the microscopic protozoan parasite *Cryptosporidium parvum*. In persons with normal immune functions, the diarrhea caused by *C. parvum* may be intense and prolonged, but is self-limiting. In AIDS patients, cryptosporidial diarrhea is often life-threatening. It is estimated that 15-20 percent of AIDS patients suffer from this condition. Up to now, there has been no consistently effective or approved therapy for cryptosporidiosis.

The most frequently identified pathogen in AIDS patients is *Enterocytozoon bieneusi*, a microsporidian parasite, which was found in nearly one-quarter of the patients. It now appears that this tiny parasite may turn out to be the cause of a large proportion of the many unexplained cases of malabsorption, diarrhea and wasting seen in HIV-ill patients. There is no known effective treatment as yet.

Several other species of microsporidia infect HIV-positive patients, including *Encephalitozoon hellem* and *cuniculi*, and a new species designated *Septata intestinalis*. A recent report suggests that disseminated microsporidia infections are increasing in significance.

Infection with the parasite *Isospora belli* is clinically indistinguishable from cryptosporidiosis. More common in tropical climates, *I. belli* has been reported in less than 1% of patients in the U.S., although its actual incidence is probably higher.

Pneumocystis carinii has generally been classified as a protozoan parasite; some studies indicate it may be a fungus, with which it shares certain genetic sequences. *P. carinii* usually infects the lungs (Pneumocystis Carinii Pneumonia (PCP)). Therapy is reported to be successful in about 40-60% of patients, with problems including drug toxicity particularly in immunocompromised patients. Among the many serious manifestations of human immunodeficiency virus (HIV) infection in children, PCP stands out because of its high incidence, unique age distribution, and frequent mortality. PCP is the most common serious opportunistic infection in children with HIV infection; the incidence of PCP among HIV-infected infants not receiving prophylaxis is estimated to be at least 12% in the first year of life. Many children die shortly after PCP develops.

Mycobacterium Avium Complex (MAC) refers to infections by a family of very similar mycobacterial organisms, *Mycobacterium avium* and *M. intracellulare*. When MAC occurs in non-immunocompromised people, it is usually in the form of infection in the respiratory tract. In patients with AIDS, MAC is frequently disseminated (disseminated MAC or DMAC), and almost any organ system can be involved. In a recent study, MAC bacterial was found in 43% of patients who survived for 2 years after an AIDS diagnosis. No standard therapy has been

established for disseminated MAC. Combinations of drugs are usually prescribed and, if successful, require that treatment be continued for life. A more effective treatment is urgently needed.

The HIV-infected are particularly susceptible to infection by *Mycobacterium tuberculosis*, and the course of the disease is accelerated. While extrapulmonary tuberculosis is unusual in non-HIV-infected patients, it frequently occurs in HIV-positive people. The CDC has released guidelines for the treatment of TB which address the growing prevalence of multi-drug resistant TB (MDR-TB). Mortality among AIDS patients with MDR-TB is very high (approximately 80%) and the disease progression is extremely rapid.

Accordingly, there is an urgent need for the development of a method of treatment of these infections so prevalent in, and threatening to, humans and animals.

There is also a need for a broad-acting drug for simplification of treatment of trematode infections. Presently, it is necessary to diagnose the specific trematode pathogen, and then to prescribe the drug therapy specific for that trematode. Many lesser developed countries are not equipped to diagnose a the specific trematode. Development of a broad acting drug would eliminate the requirement for diagnosis.

Schistosoma mansoni, the blood fluke, is the causative agent of Schistosomiasis, the second most important tropical parasitic disease of man (after Malaria), and the most important trematode infection of man. *Schistosoma haematobium* is another important species infecting man. Over 200 million individuals suffer from schistosomiasis world wide, including several hundred thousand people in the United States.

Fasciola hepatica, the common liver fluke, is primarily a disease of sheep, but humans are an accidental host. The parasite manages to survive in the presence of a vigorous host immune response. Bithionol has been suggested for treatment, but is not approved for use in the United States.

There is thus a need for a pharmaceutical composition which is storage stable even in tropical environments, and which is broad acting against trematodes.

Summary of the Invention

It has now been observed in animal studies and in human clinical studies that the efficacy of a treatment, using the compounds of formula (I) and (II) is dependent upon the particle size of the active drug substance and the stability of the compounds.


The pharmaceutical compositions described are suitable for treating human and animal trematode infections caused by *Schistosoma* such as *Schistosoma mansoni*, *Schistosoma haematobium*, *Schistosoma mekongi*, *Schistosoma japonicum*, *Schistosoma intercalatum*; *Fasciola* such as *Fasciola hepatica* and *Fasciola gigantica*, *Fasciolopsis biski*; and *Dicrocoelium dendriticum*, *Heterophyes heterophyes*, and *Metagonimus yokogawa*.

The pharmaceutical compositions are also effective for treatment in the immuno-compromised of opportunistic infections of *Cryptosporidium parvum*, *Isospora belli*, *Enterocytozoon bieneusi*, *Encephalitozoon intestinalis*, *Mycobacterium tuberculosis*, *Mycobacterium avium intracellulare*, *Pneumocystis carinii*, and *Toxoplasma gondii*.


The pharmaceutical composition may be in a form suitable for oral administration, as a solid dosage form, a liquid suspension, or a paste.

Detailed Description of the Invention

The method for treatment of infections of the present invention comprises administration of a pharmaceutical composition comprising, as active agent, at least one compound selected from the group consisting of desacetyl-nitazoxanide of formula (I):



and nitazoxanide of formula (II):



Nitazoxanide (NTZ), the compound of formula (II), is the generic name for 2-(acetolyloxy)-N-(5-nitro 2-thiazoly) benzamide, a compound first synthesized by Rossignol and Cavier in 1975. 2 mg of nitazoxanide can be dissolved in 1 ml DMSO. Nitazoxanide is easily absorbed orally.

Until now there has been no evidence that the compounds of formula (I) and/or (II) could be broadly effective against trematode infections, or that they would be sufficiently non-toxic to be tolerated by even immuno-compromised humans.

The preparation and certain uses of nitazoxanide is disclosed in US Patent 3,950,351, as well as in publications by the present inventor. Desacetyl-nitazoxanide, the compound of formula (I), is sometimes referred to as tizoxanide or d-NTZ, and is a metabolite of nitazoxanide.

In WO 95/28393, the present inventor disclosed a method for the manufacture of pure compound of formula (II), as well as the use of the composition containing a mixture of compounds of formula (I) and (II).

It has now been observed that solid particles of compound of formula (I), compound of formula (II), or mixtures thereof having a particle size between 170 and 520 μm (mean particle size = 352 μm) have very limited efficacy when administered orally to animals or humans. The efficacy of such particles is inferior to existing pharmaceutical products and therefore unacceptable for regulatory or commercial purposes.

It has also been observed in dogs that the oral administration of a single dose of 50 milligrams per kilogram of solid particles of compound of formula (I) and compound of formula (II) having a particle size smaller than 5 μm , caused severe adverse reactions in the animals.

It has now been discovered that in order to have an effective and safe treatment of infections caused by parasites, bacteria, fungi and viruses in humans and animals, the pharmaceutical composition, either a solid dosage form or an aqueous suspension, must contain the effective dose of the active agent in the form of solid particles having a particle size smaller than 200 μm and containing compound of formula (I) and/or compound of formula (II), the mean particle size of the active solid particles being greater than 10 μm .

The presence of a high content of particles of active agent having a size larger than 200 μm with respect to the content of particles having a size between 5 and 200 μm significantly reduces the chemotherapeutic activity of the compounds. Preferably, the pharmaceutical compositions of the invention do not contain more than 5% by weight of active solid particles having a size larger than 200 μm . Most preferably, the pharmaceutical compositions of the invention contain substantially no active solid particles having a size larger than 200 μm .

The presence of a high content of particles of active agent having a size less than 5 μm with respect to the content of particles having a size between 5 and 200 μm can produce adverse effects in animals or in humans. In addition, it has been observed that particles having a size less than 5 μm are more rapidly absorbed from the gastro-intestinal tract into the bloodstream, and

therefore are not as effective against parasites, bacteria, fungi and viruses which commonly live within the gastro-intestinal tract of animals and humans.

The skilled scientist could not predict that the particle size of compound of formula (I) and compound of formula (II) would have such a significant impact upon its antimicrobial activity in animals and in humans. For example, in studies conducted by the Inventor, anti-parasitic compounds such as albendazole, mebendazole, niclosamide, praziquantel and metronidazole have not demonstrated such a marked difference in anti-parasitic activity in animals or humans which was dependent upon their particle size. In addition, a skilled scientist could not predict that particle sizes of compound of formula (I) and compound of formula (II) would have such an adverse impact upon the ability of animals or humans to tolerate the administration of said active agent.

The compound(s) of formula (I) and (II) may be administered in either a solid dosage form or an aqueous suspension, and it is preferred that the pharmaceutical composition contain the effective dose of the active agent in the form of solid particles of formula (I) and/or (II) having a particle size smaller than 200 μm , the mean particle size of said active solid particles being greater than 10 μm as determined by a Coulter® Counter LS 100. This equipment uses laser light at 750 nm to size particles from 0.4 to 900 μm in diameter by light diffraction. The samples are measured in water with a small amount of Triton X-100 in order to increase the wettability and deflocculate the powder.

Advantageously, the mean particle size of said active solid particles is between 10 and 100 μm , preferably between 20 and 50 μm . Examples of preferred compositions are:

- a composition for which less than 10% by weight of said active solid particles has a particle size larger than 100 μm ;
- a composition for which at least 50% by weight of said active solid particles has a particle size smaller than 50 μm .

Advantageously, the mean particle size of said active solid particles is between 10 and 100 μm , preferably between 20 and 50 μm . In accordance with a preferred embodiment of the composition, less than 10% of said active solid particles has a particle size smaller than 5 μm .

The active agent or agents used in the solid dosage form or suspension is advantageously a mixture of solid particles of compounds of formula (I) and of formula (II) with a particle size smaller than 200 μm , the weight content of compound of formula (I) with respect to the weight of compounds of formula (I) and of formula (II) of said mixture being comprised between 0.5 and 20%, preferably between 0.5 and 10%.

The invention also relates to pharmaceutical compositions described above which contain advantageously at least one pharmaceutically acceptable acid. Examples of such acids are: citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartaric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof. Citric acid is very appropriate. The presence of said acid improves the stability of the active agent or agents.

The ratio of the weight of pharmaceutically acceptable acid/the weight of said active solid particles is advantageously between 0.01 and 0.5, preferably between 0.03 and 0.2. Advantageously, the amount of acid is sufficient for adjusting the pH of the suspension between 2 and 6, preferably between 3 and 5, most preferably between 3.5 and 4.5.

Techniques for preparation of, and preferred examples of, solid and liquid dosage forms of the pharmaceutical composition are disclosed in WO/95/28393, the disclosure of which is incorporated herein by reference. The compositions contain advantageously a wetting agent and possibly a starch derivative such as those disclosed in US Patent 5,578,621, the content of which is incorporated herein by reference for disclosing possible wetting agents and starch derivatives. The wetting agent as described in US 5,578,621 serves as a dispersing agent.

Such pharmaceutical compositions, either as solid or liquid dosage forms or as pastes or ointments, can optionally contain additional active agents such as antibiotics, anti-viral agents or proton pump inhibitors. While it is not advantageous, it is also possible that such pharmaceutical formulations contain active solid particles of compound of formula (I) and/or compound of formula (II) which are larger than 200 μm .

The compositions can contain excipients known as such for the purpose of preparing forms suitable for oral administration.

Advantageously, in order to have excellent efficacy against a broad spectrum of parasites, bacteria, fungi and viruses, the distribution factor of said active solid particles is between 0.8 and 2, preferably between 1.1 and 1.9, most preferably greater than 1.5, said distribution factor being calculated by the following formula:

$$F_{90\%} = (\varnothing_{90\%} - \varnothing_{10\%}) / ((\varnothing_{90\%} + \varnothing_{10\%}) / 2)$$

in which

- $F_{90\%}$ is the distribution factor at 90%;
- $\varnothing_{90\%}$ is the maximum particle size of the fraction of particles corresponding to 90% of said active solid particles, and
- $\varnothing_{10\%}$ is the maximum particle size of the fraction of particles corresponding to 10% of said active solid particles.

According to a specific embodiment of the invention, particles of a compound of formula (I) and/or (II) are prepared by the methods described hereabove and are then milled so that less than 10% of said active particles are larger than 100 μm , less than 50% of said particles are larger than 50 μm and less than 10% of said active particles are smaller than 5 μm in size, the mean particle size being between 20 and 50 μm . Said active particles are then granulated using a mixture containing active solid particles and at least one granulating agent. Examples of granulating agent are: polyvinylpyrrolidone, water, alcohol, sucrose hydroxyl cellulose and mixture thereof. Advantageously, at least one pharmaceutically acceptable acid is added during the granulation process.

The invention relates to solid dosage forms containing a composition of the invention such as tablets, dispersible tablets, coated tablets, matrixes, etc. The dosage form of the invention contains, for example:

- solid active particles with a particle size smaller than 200 μm , less than 10% of said particles having a size larger than 100 μm , less than 50% of said particles having a size larger than 50 μm and less than 10% of said particles having a size less than 5 μm , the mean particle size being between 20 and 50 μm .
- at least one granulating agent;
- at least one wetting agent;
- at least one starch derivative, and
- at least one pharmaceutically acceptable acid which is preferably added during the granulation process.

Liquid dosage forms such as aqueous suspensions of the invention contain, for example:

- as active agent, solid particles containing a compound of formula (I) and/or a compound of formula (II) having a particle size smaller than 200 μm , less than 10% of said particles having a size larger than 100 μm , less than 50% of said particles having a size larger than 50 μm and less than 10% of said particles having a size less than 5 μm , and
- at least one granulating agent;
- at least one wetting agent;
- at least one pharmaceutically acceptable acid, the pH of the suspension being between 2 and 6, preferably between 3 and 5, most preferably between 3.5 and 4.5;
- at least one thickener, for example a Xanthan gum, aguar gum, crystalline cellulose, carruba gum, carboxymethylcellulose or a mixture thereof.

Paste or ointment forms of the invention suitable for oral administration contain, for example:

- as active agent, solid particles containing a compound of formula (I) and/or a compound of formula (II) having a particle size smaller than 200 μm , less than 10% of said particles having a size larger than 100 μm , less than 50% of said particles having a size larger than 50 μm and less than 10% of said particles having a size less than 5 μm , and
- at least one wetting agent;
- at least one pharmaceutically acceptable acid, the pH of the suspension being between 2 and 6, preferably between 3 and 5, most preferably between 3.5 and 4.5;
- at least one thickener, for example a Xanthan gum, aguar gum, crystalline cellulose, carruba gum, carboxymethylcellulose or a mixture thereof.

Paste or ointment forms for topical or intravaginal application contain, for example:

- as active agent, solid particles containing a compound of formula (I) and/or a compound of formula (II) having a particle size smaller than 200 μm , less than 10% of said particles having a size larger than 100 μm , less than 50% of said particles having a size larger than 50 μm and less than 10% of said particles having a size less than 5 μm , and
- at least one wetting agent;
- at least one pharmaceutically acceptable acid, the pH of the suspension being between 2 and 6, preferably between 3 and 5, most preferably between 3.5 and 4.5;
- cetylic alcohol and/or glyceride derivatives and/or propyleneglycol;
- at least one thickener, for example a Xanthan gum, aguar gum, crystalline cellulose, carruba gum, carboxymethylcellulose or a mixture thereof.

Description of Preparation of Pharmaceutical Compositions

Dry pure compound of formula (I) and dry pure compound of formula (II) were submitted to grinding and sized by means of a mesh screen.

After grinding, the particles of compound of formula (I), of formula (II) and mixtures thereof usually had the particle size distribution as follows:

- less than 10% by weight of the particles had a particle size smaller than approximately 5 μm ;
- less than 10% by weight of the particles had a particle size larger than approximately 70 μm ;
- the mean particle size is approximately 40 μm ;

The distribution factor of the particles is about 1.73, said distribution factor being calculated by the following formula:

$$F_{90\%} = (\varnothing_{90\%} - \varnothing_{10\%}) / ((\varnothing_{90\%} + \varnothing_{10\%}) / 2)$$

in which

- $F_{90\%}$ is the distribution factor at 90%;
- $\varnothing_{90\%}$ is the maximum particle size of the fraction of particles corresponding to 90% of said active solid particles, and
- $\varnothing_{10\%}$ is the maximum particle size of the fraction of particles corresponding to 10% of said active solid particles.

Specific examples of such compositions are disclosed in the following Tables.

Table 1. Example of composition of dispersible tablets for oral administration containing compound of formula (II) and compound of formula (I) as active agents.

Nitazoxanide (99%) + desacetyl-nitazoxanide (1%)	200 mg
Microcrystalline cellulose	
Avicel pH 102 sold by FMC-USA	116 mg
Crospovidone	25 mg
Magnesium stearate	3 mg
Colloidal silicon dioxide	5 mg
Citric acid	10 mg
Strawberry flavor No. 877720 sold by Robertet	10 mg
Sodium saccharinate	2 mg

Table 2. Example of composition of coated tablets for oral administration containing compound of formula (II) and compound of formula (I) as active agents.

Nitazoxanide	500 mg
Maize starch	60 mg
Pregelatinized Maize starch	70 mg
Hydroxypropyl methylcellulose	5 mg
Sucrose	20 mg
Sodium starch glycollate	30 mg
Citric acid	25 mg
Talc	8 mg
Magnesium stearate	7 mg

Coatings:

Hot sugar solution or a film coating being sprayed on the tablets or granules containing 500 mg active agent

Table 3. Example of an aqueous suspension for oral administration containing compound of formula (II) and compound of formula (I) as active agents. The pH of the suspension was about 4.1.

Nitazoxanide (98%) + desacetyl-Nitazoxanide (2%)	2 g
Distilled water	100 ml
Sodium benzoate	0.2 g
Saccharose	30.5 g
Xanthan gum	0.2 g
Microcrystalline cellulose and carboxymethylcellulose sodium	
Avicel RC-591 sold by FMC - USA	0.8 g
Citric acid	0.2 g
Dihydrated sodium citrate	50 mg
Strawberry flavor No. 877720 sold by Robertet	125 mg
Red dye No. 33 D and C	1 mg

Table 4. Example of a paste for oral administration containing compound of formula (II) and compound of formula (I) as active agents.

Nitazoxanide (98%) + desacetyl-Nitazoxanide (2%)	500 mg
Mineral oil	10 g
Brown sugar	1 g
Microcrystalline cellulose and carboxymethylcellulose sodium	
Avicel RC-591 sold by FMC	0.8 g
Citric acid	0.2 g

Table 5. Example of a paste or ointment formulation for intravaginal or topical application, said paste or ointment containing compound of formula (II) and compound of formula (I) as active agents.

Nitazoxanide (98%) + desacetyl-Nitazoxanide (2%)	8 g
Cremaphor A6	2 g
Cremaphor A25	1.5 g
Mineral oil	7 g
Luvitol EHO	7 g
Glycerol monoester	4 g
Cetylic alcohol	3 g
Simeticone	0.5 g
Germaben II	1 g
Propyleneglycol	3.5 g
Distilled water	62.5 g

The pharmaceutical compositions of the invention are compositions having a broad spectrum of action on parasites, bacteria, fungi and viruses, especially when administered orally.

The efficacy and the safety of the pharmaceutical compositions disclosed hereabove were excellent in animals and in humans. Specifically, in human clinical studies, it has been observed that the efficacy of the pharmaceutical compositions described hereabove are significantly more effective in treating parasitic infections than the same formulations using active compound having particle sizes between 170 and 520 μm (mean particle size = 352 μm), even when the larger sized

particles were administered to patients at doses up to three times higher and for longer periods of time. Examples of cure rates obtained are shown below in Table 6.

Table 6. Comparison of results of human clinical studies using compounds of formula (I) and formula (II) having particle sizes ranging from 170 μm to 520 μm (mean = 352 μm) with results obtained using formula (I) and formula (II) having particle sizes ranging from 5 μm to 200 μm (mean = 34 μm).

Compound of formula (I) (98%) + Compound of formula (II) (2%)

Parasite	<i>Particle sizes 170 to 520 μm</i>	<i>Particle sizes 5 to 200 μm</i>
	<i>Dose = 15 to 50 mg/kg/day for 3 to 7 days</i>	<i>Dose = 15 mg/kg/day for 3 days</i>
	No. Cured/Total = % Cure Rate	No. Cured/Total = % Cure Rate
Blastocystis hominis	12/27 = 44%	10/10 = 100%
Entamoeba histolytica	29/47 = 62%	106/133 = 80%
Giardia lamblia	11/37 = 30%	50/73 = 68%
Ascaris lumbricoides	3/69 = 4%	144/179 = 80%
Trichuris trichiura	7/48 = 15%	58/79 = 73%

For each of the parasites listed in Table 6, the proportional cure rates were significantly better for the patients treated with active particles between 5 and 200 μm than for those treated with active particles ranging from 170 μm to 520 μm in size, with a statistical significance in each case being $p < 0.02$ (using a standard X^2 test). This was the case even though the doses of the larger particle size active agent were usually higher and the duration of treatment was often longer than that administered to the patients receiving pharmaceutical compositions of active agent having particle sizes smaller than 200 μm . There were no serious adverse effects reported for either group of patients.

Results similar to those described above for human studies have also been observed in animal testing.

In addition, the adverse reactions observed in dogs after oral administration of a single dose of 50 milligrams per kilogram of compound of formula (I) and compound of formula (II) have not been observed in extensive studies in animals using compound of formula (I) and compound of formula (II) having a particle size between 5 and 200 μm (mean > 10 μm), even when the same dose or a higher dose of the compounds were administered daily for 90 days or longer.

Moreover, said compositions were stable (even when subjected to temperatures of 40° C and 65% relative humidity for six months or, in the case of liquid suspensions, when suspended in water under these conditions for 3 months) thereby assuring that the active ingredients do not

degrade and that the compositions maintain their efficacy for a period of time after their preparation which is suitable for medicinal and commercial purposes.

In the following, efficacy of the pharmaceutical compositions will be demonstrated.

EXAMPLE I

CRYPTOSPORIDIUM PARVUM

In a preliminary clinical trial, 30 AIDS patients with chronic cryptosporidial diarrhea were treated with oral nitazoxanide from 500 to 2000 mg daily. If the diarrhea continued, the patients received an additional four weeks of nitazoxanide, up to 2000 mg a day.

Twenty-eight people completed two or more weeks of therapy and 16 of those were evaluable for a therapeutic response by the eighth week of treatment. In this latter group, 12 persons had a 50 percent or greater reduction in daily bowel movement frequency and 10 individuals had a marked reduction or eradication of the parasite in the stool, with the organism becoming undetectable in four people. Six patients met both clinical and parasitological response criteria for benefit.

Patients who received higher daily doses of drug for longer periods of time were more likely to have a positive response.

An open-label study of nitazoxanide for AIDS-related cryptosporidial diarrhea documented decreased bowel movements among persons taking 500, 1000, 1500, or 2000 mg of the drug daily. Trial participants had a mean CD4+ count of 42 cells/mm³ (range 0-303 cells/mm³), a mean 6.7 bowel movements daily for an average 15 months, *Cryptosporidium parvum* oocysts in stool, and no other apparent enteric pathogens. Almost all participants had failed therapy with azithromycin or paromomycin.

After 23 weeks, 9 of 13 had a complete clinical response (one to three predominantly formed bowel movements daily), and 4 of 13 had a partial clinical response (at least a 50 percent decrease in daily bowel movements or a change in stool consistency so that at least 75 percent were formed). By the end of the study, 8 of 11 had completely eradicated the parasite and the other three had substantial reductions in oocyst levels. There was a trend toward better response with doses of 1000 mg daily or higher and with longer therapy. Two trial participants had urticarial skin rashes; more than 90 percent adhered to the study regimen for more than four weeks.

EXAMPLE II

CRYPTOSPORIDIUM PARVUM

In vitro Dose Information:

Nitazoxanide was dissolved in sterile dimethylsulfoxide (DMSO) and tested against intact *C. parvum* oocysts infected cell monolayers at concentrations of 100 µg/ml, 10 µg/ml/1 µg/ml

and 0.1 µg/ml. A second trial was performed which tested nitazoxanide at the additional concentrations of 20, 2, 0.2 and 0.02 µg/ml. These concentrations were achieved by serial dilutions with complete DMEM medium to yield a final DMSO concentration of 0.5%. The medium control also contained 0.5% DMSO.

The experiment used a cell culture of MDBKF5D2 Cells grown in 7 mm chambers, and as *Cryptosporidium parvum*: GCH1 oocysts, 5×10^4 per well, and was conducted to compare paromomycin (positive control) against nitazoxanide (experimental drug). Materials included Immune Anti-*Cryptosporidium parvum* Sporozoite Rabbit Serum (0.1%) and Fluorescein-Conjugated Goat Anti-Rabbit Antibody (1%).

Toxicity Testing Assay:

200µl of medium containing nitazoxanide at concentrations of 100, 10, 1 and 0.1 µg/ml and the proper controls were introduced into two wells of a 96 well plate containing confluent MDBKF5D2 cell monolayers and two wells without monolayers. The drug was incubated on the monolayers at 37°C and 8% CO₂. At 24 hours (trial 1) and 48 hours (trial 2), MTS (Owen's solution) the PMS were added to each well at concentrations of 333 µg/ml and 25 µM respectively. The plate was returned to the incubator in the dark to develop for two hours. At two hours, 100 µl of each supernatant was transferred to a new microtiter plate and read in the ELISA reader at 490nm. Results were recorded and analyzed. Percent toxicity was calculated by subtracting the mean optical density (OD) of the drug supernatants from the mean optical density (OD) of the medium control supernatants (no drug), dividing by the OD of the medium control and multiplying by 100.

$$\frac{\text{OD medium} - \text{OD drug}}{\text{OD medium}} \times 100$$

Intact *C. parvum* Oocyst Assay:

5×10^4 *C. parvum* oocysts per well were incubated in nitazoxanide (100, 20, 10, 2, 1, 0.2, 0.1 and 0.02 µg/ml) at 37°C (8% CO₂) on confluent MDBKF5D2 cell monolayers. The level of infection in each well was determined and analyzed by an immunofluorescence assay at 24 to 48 hours. Percent Inhibition was calculated by subtracting the mean parasite count/10 field in the drug test wells from the mean parasite count/10 fields in the medium control (no drug), dividing by the medium control count, and then multiplying by 100.

$$\frac{\text{Medium control count} - \text{Drug test count}}{\text{Medium control count}} \times 100$$

Medium control count

Results:

Trial 1: 24 hrs.

Compound	Conc.	Mean (+ SD)*	Percent Toxicity	Percent Inhibition
Infected Media	0	983.5(±128.2)	0	0
Paromomycin	2 mg/ml	482(±47.1)	23.8	51
NTZ	100µg/ml	Lost	88.1	NA**
	10µg/ml	55.5(±13.5)	65.1	94.4
	1µg/ml	224.5(±28.5)	8.3	77.2
	0.1µg/ml	474.5(±29.5)	19.3	51.8

* Parasite Count/10 Fields

**Not available due to toxicity

Trial 2: 48 hrs.

Compound	Conc.	Mean (+ SD)*	Percent Toxicity	Percent Inhibition
Infected Media	0	2231.25(+90.03)	0	0
Paromomycin	2 mg/ml	580(+33.42)	40.8	74.01
NTZ	20µg/ml	68.75(+13.77)	92.87	96.92
	2µg/ml	113.75(+21.36)	24.93	94.90
	0.2µg/ml	1020(+158.48)	16.56	54.29
	0.02µg/ml	1041(+191.46)	21.23	53.33

* Parasite Count/10 Fields

Impact of nitazoxanide on the intact *C. parvum* oocysts:

In trial 1, nitazoxanide at concentrations of 10, 1 and 0.1 resulted in parasite inhibition levels of 94.4, 77.2 and 51.8%, respectively, and cell toxicity levels of 65.1, 8.3 and 19.3%

respectively. Although nearly complete inhibition of parasite infection occurred in 10 µg/ml, a high toxicity rating was evident. At 1 µg/ml of nitazoxanide, parasite inhibition and cellular toxicity compared favorably to paromomycin at a concentration of 2 mg/ml (77.2% parasite inhibition and 8.3% toxicity for nitazoxanide at 1 µg/ml compared to 51% parasite inhibition and 23.8% cell toxicity for paromomycin at 2 mg/ml).

In trial 2, the drug was modified to obtain better dose distribution with minimum toxicity. Consequently, the cultures remained viable for 48 hours instead of 24 hours as in trial 1. Incubation for 48 hours clearly resulted in higher relative cell toxicity as evident from examination of paromomycin in both trials. The 20 µg/ml concentration of nitazoxanide was still too toxic at 48 hours incubation although the cell monolayer appeared still intact. It is possible that high toxicity which must affect cell function also impacts parasite infection/development. At 2 µg/ml of nitazoxanide, there was a considerable inhibition of the parasite infection with relatively low cellular toxicity. Further dilutions also resulted in significant inhibition and low toxicity. At a drug concentration of 2 µg/ml, moderate cell toxicity and inhibitory activity of 94.90% indicates that nitazoxanide at 2 µg/ml is superior to paromomycin for *in vitro* *C. parvum* infection at 2 mg/ml (e.g. 1000 times higher concentration).

EXAMPLE III

CRYPTOSPORIDIUM PARVUM

In vitro Dose and Storage Information:

Stocks of nitazoxanide and desacetyl-nitazoxanide (NTZ and NTZdes) were tested against intact *C. parvum* oocysts and excysted sporozoite infected cell monolayers at concentrations 10, 1, 0.1 and 0.01 µg/ml. Each compound was dissolved in 100% dimethyl sulfoxide (DMSO) and diluted to the desired concentrations with sterile DMEM. Each concentration of nitazoxanide and the media controls contained 0.025% DMSO as a constant.

The experiment used a cell culture of MDBKF5D2 Cells grown in 7 mm chambers, and as *Cryptosporidium parvum*: GCH1 oocysts, 5×10^4 per well, and was conducted to compare paromomycin (positive control) against nitazoxanide (experimental drug). Materials included Immune Anti-*Cryptosporidium parvum* Sporozoite Rabbit Serum (0.1%) and Fluorescein-Conjugated Goat Anti-Rabbit Antibody (1%).

Toxicity Testing Assay:

200µl of medium containing nitazoxanide solution at the pre-mentioned concentrations and the proper controls were introduced into two wells of a 96 well plate containing confluent

MDBKFD2 cell monolayers and two wells without monolayers. The drug was incubated on the monolayers at 37°C and 8% CO₂. At 48 hours, MTS (Owen's solution) and PMS were added to each well at concentrations of 333 µg/ml and 25 µM respectively. The plate was returned to the incubator in the dark to develop for 2 hours. At 2 hours, 100 µl of each supernatant was transferred to a new microtiter plate and read in the ELISA reader at 490 nm. Results were recorded and analyzed. Percent toxicity was calculated by subtracting the mean optical density (OD) of the drug supernatants from the mean OD of the medium control supernatants (no drug), dividing by the OD of the medium control and multiplying by 100.

$$\frac{\text{OD medium} - \text{OD drug} \times 100}{\text{OD medium}}$$

Cytotoxicity scores were assigned as follows: 0.5% toxicity = 0, 6-25% toxicity = 1, 26-50% toxicity = 2, 51-75% toxicity = 3 and 76-100% toxicity = 4. As a standard, cytotoxicity scores of 0 or 1 are to be considered acceptable levels of toxicity. Toxicity scores of 2, 3 or 4 are considered a high level of toxicity to the cell monolayer.

Intact *C. parvum* oocyst Assay:

5 x 10⁴ *C. parvum* oocysts per well are incubated in the pre-mentioned concentrations of nitazoxanide at 37°C (8% CO₂) on confluent MDBKF5D2 cell monolayers. The level of infection in each well was determined and computer analyzed by an immunofluorescence assay at 48 hours. Percent Inhibition was calculated by subtracting the mean parasite count/field in the drug test wells from the mean parasite count/field in medium control (no drug), dividing by the medium control count and multiplying by 100.

$$\frac{\text{Medium control count} - \text{Drug test count}}{\text{Medium control count}} \times 100$$

Results:*C. parvum* Oocysts Assay (48 hr.)

Drugs	Conc	Parasite	±SD	Tox/O D	±SD	%Inhib	%Tox	Score
Aqueous Media	0	681.58	±271.02	2.024	±0.18	0	0	0
Paromomycin	2000	115.75	±44.65	1.219	±.009	83.02	39.79	2
0.025% DMSO Media	0	628.50	±171.94	1.799	±1.45	0	0	0
NTZ	10	11.75	±7.33	.413	±0.13	98.13	77.07	4
	1	39.67	±13.13	1.618	±.326	93.69	10.09	1
	0.1	643.42	±229.73	1.878	±.154	≤0	≤0	0
	0.01	714.33	±194.79	1.617	±.072	≤0	10.12	1
New NTZdes	10	13.75	±6.66	.337	±.005	97.81	81.27	4
	1	39.92	±13.49	1.710	±.033	93.65	4.97	0
	0.1	649.86	±152.19	1.506	±.119	≤0	16.29	1
	0.01	749.33	±139.49	1.721	±.144	≤0	4.36	0

Conc. - µg/ml; Parasite - Mean parasite count/field (12 fields analyzed); %Inhib - Percent inhibition of parasite infection; % Tox - Percent toxicity to cells by the drug.

It can be seen from the above that the Inhibitory activity of NTZdes was the same as NTZ of Example II.

Both nitazoxanide and desacetyl nitazoxanide were equally effective in vitro against *Cryptosporidium parvum* when tested in parallel with 98 and 94% inhibitions obtained with 10 and 1 µg/ml for each compound respectively. For nitazoxanide 1 µg/ml was the lowest concentration giving more than 90% of inhibition while 50% inhibition could be obtained with lower concentrations of nitazoxanide such as 0.2, 0.1 and 0.02 µg/ml. In the same experimental condition paromomycin used as positive control was 2,000 times less effective with inhibitory concentrations ranging from 51 to 83% at a concentration of 2,000 µg/ml.

EXAMPLE IV*E. INTESTINALIS* AND *V. CORNEA*

2RK-13 cells (rabbit kidney cell line) were added to 24-well culture plates at a concentration of 2.6×10^5 cells per well (1.0 ml medium; RPMI 1640 with 2 mM L-glutamine and 5% heat-inactivated fetal bovine serum). Dishes were incubated at 37°C in a CO₂ incubator overnight at which time the wells were confluent (with one doubling, would estimate 5×10^5 cells per well).

Septata intestinalis (tissue culture-derived) organisms were added to the host cells at a 3:1 ratio compared with the estimated host cells or at 15×10^6 organisms per well. This ratio resulted in approximately 50% of the host cells becoming infected).

Drugs were dissolved in DMSO, water or methanol (depending on solubility) to generate stocks of 1.0 mg/ml. Stocks were stored at -70°C . Dilutions used in experiments are made in complete tissue culture medium. All dilutions are tested in triplicate well.

Medium is replaced every three-to-four days (containing freshly-diluted drugs).

On day six (after adding parasites and drugs), the cells are examined for toxicity. Control cells given drugs but no parasites are examined for confluency, morphology of cells, and presence of dead or floating cells. Cells incubated with parasites only are examined to confirm that parasites are infectious (i.e. presence of parasitophorous vacuoles). Cells incubated with parasites and drugs are evaluated for host cell toxicity and relative numbers of parasitophorous vacuoles (i.e. high, medium, or low).

On day ten, 100 μl of 10% SDS (0.5% final concentration) was added to the culture wells to disrupt host cell membranes and cause release of the microsporidia. The total number of parasites present in each well was determined by counting an aliquot on a hemacytometer. Results are expressed as percent inhibition (relative to infected cells given no drug).

EXAMPLE V

TOXOPLASMA GONDII

Nitazoxanide and desacetyl nitazoxanide were tested against parasites, and more specifically, RH strain of *Toxoplasma gondii*, maintained by serial passages in mice. Cell cultures of MRC5 fibroblasts (Bio-Merieux, France) cultured in 96-well microplates were inoculated with *T. gondii*. 200 freshly harvested tachyzoites were added into each culture well, except in 8 control wells (negative controls). After 4 hours of incubation, drug dilutions were added into the cultures.

Nitazoxanide (NTZ) and desacetyl nitazoxanide (dNTZ) were tested at concentrations ranging between $8 \cdot 10^{-4}$ and 40 mg/L. Drugs were initially dissolved in DMSO, at a concentration of 2 mg/mL, then serial dilutions were prepared in the culture medium. No precipitate was observed.

Drug dilutions were added into the cultures (8 wells for each dilution) then culture plates were incubated for 72 hours. Cultures were then fixed with cold methanol. Assessment of growth of *T. gondii* was performed by ELISA using a peroxidase labeled rabbit anti *T. gondii* antibody. Optical density values were recorded for each well.

Results are presented by plotting the OD values obtained for each culture well, vs the concentration of the drug in the culture. Statistical analysis consisted in regression analysis with

95% confidence interval and determination of dose-response curves, from the OD values generated for each drug.

One plate was stained with Giemsa to examine the cytopathic effect in the cultures.

Three separate experiments were realized. In each experiment, two culture plates were used for each compound; in each culture plate, 8 replicate wells were used for each drug concentration.

Results:

Similar results were obtained in the three sets of experiments.

Nitazoxanide:

No inhibitory effect was noted for concentrations ranging between 10^{-4} mg/L and 0.3 mg/L. A significant effect was noted for concentration ≥ 0.6 mg/L, with a complete inhibition of *Toxoplasma* growth for concentrations ≥ 2.5 mg/L. However, a marked toxicity was noted on the cell monolayer for concentrations ≥ 2.5 mg/L.

Microscopic examination of the monolayer showed that NTZ, at a concentration of 1.25 mg/L induced cytopathic effect on the parasitized cells, with enlargement of the parasitophorous vacuole and reduction of the number of the intra-cellular parasites. From regression analysis, the 50% inhibitory concentration could be estimated at 1.2 mg/L.

Deacetyl nitazoxanide:

Similar results were obtained with deacetyl nitazoxanide: no effect for concentrations ranging between 10^{-4} mg/L and 0.3 mg/L, inhibition for concentration ≥ 0.6 mg/L, and marked toxicity for concentration ≥ 2.5 mg/L. The 50% inhibitory concentration could be estimated at 1.2 mg/L.

The results obtained were reproducible over three separate experiments, with assessment of the drug inhibitory effect on repeated cultures for each drug concentration.

For both NTZ and deacetyl NTZ, a marked inhibition of *Toxoplasma* growth could be observed at concentrations of approximately 1.2 mg/L, with alteration of the parasitophorous vacuole but no marked alteration of the parasite itself.

These results indicate that these drugs have good activity against *T. gondii*, and that a therapeutic effect can be expected in vivo based on obtaining a concentration of approximately 1 mg/L in serum or tissues.

EXAMPLE VI
MYCOBACTERIA

Nitazoxanide was found to have antimicrobial activity against TB organisms. The following table shows an assay for MIC of nitazoxanide and tizoxanide against *Mycobacterium intracellulare* by agar dilution technique. These results are based upon several experiments, each of which took about 3 weeks for the agar dilution method with Middlebrook agar. The data obtained indicate that nitazoxanide has an MIC against the Mycobacteria of 2 µg/ml and tizoxanide has an MIC of 4 µg/ml, using a standard strain of *Mycobacterium intracellulare* from ATCC, using the standard agar dilution assay.

MICs of Nitazoxanide and tizoxanide to *Mycobacterium intracellulare*

MIC	
Nitazoxanide	2 µg/ml
Tizoxanide	4 µg/ml

*MICs were determined by standard agar dilution using Middlebrook 7H11 agar for 3 weeks. *M. intracellulare* ATCC 13950, a standard strain, was used for this experiment.

For determination of nitazoxanide effectiveness against mycobacteria growing in a liquid broth we used the MTS colorimetric assay which permits us to determine growth in 4 hours rather than 3 weeks as with the agar counting method. When nitazoxanide was added at the 72 hr after culture was initiated, there was an immediate effect on continued growth as compared to the growth in control medium alone.

The 3 µg/ml dose of nitazoxanide stops growth for the next 24 hrs and then there is a slow growth afterwards for the next 2 days. The 50 µg/ml dose was completely bacteriostatic throughout the 144 hours of the culture.

EXAMPLE VII
CRYPTOSPORIDIUM PARVUM

The effect of nitazoxanide was tested against *Cryptosporidium parvum* in experimentally infected mice. Nitazoxanide was supplied by Remark Laboratories, L.C. in Tampa, Florida.

The total human dose (1 g/day for 7 days i.e. 7 g) was modified for use for mice according to Paget and Bames. The human dose was multiplied by 0.0026 for mice (weighing approximately 20 grams) to obtain the total amount of the drug needed for each host morning and

evening for 7 consecutive days. Each mouse received 2.6 mg/day (7000 mg x 0.0026/7). The doses were administered by mouth using a plastic syringe equipped with around tip needle.

Twenty (20) 2-day old suckling mice were infected by oral administration of 100,000 oocysts of *Cryptosporidium parvum* obtained from infected calves. Before being administered to mice, the oocysts were concentrated using a sugar solution according to the technique described by Fayer & Ellis. Rectal swabs from each mouse were obtained and examined daily using the modified Niehl-Neelsen staining technique described by Graczyk et al. Oocysts shedding appeared in feces 2 days after the oral infection of the animals. On the third day following infection of the animals, 10 mice received 1.3 mg of nitazoxanide, morning and evening, for 7 consecutive days while the 10 remaining mice were kept as untreated controls. Rectal swabs were obtained daily for each of the 7 days of treatment and for each of the 7 days following the end of treatment. The oocysts were suspended in oil and counted per 100 fields under a microscope.

Results:

The results shown in the following Table clearly indicate that nitazoxanide administered at a daily dose of 2.6 mg/day for 7 consecutive days was effective against *Cryptosporidium parvum* in reducing the number of oocysts in the feces of the infected mice when compared to the control animals. The test drug decreased the oocysts shedding in 6 of the 10 treated mice at the end of the third day of treatment. At the end of treatment of Day 7, there was a complete reduction of the oocyst shedding, all treatment animals having negative fecal examination when compared to untreated control mice. This effect lasted at least for 7 days after treatment as shown by negative examinations observed on days 3 and 7 after the end of treatment.

Mice No.	NO. OF OOCYST DETECTED PER OIL IMMERSION FIELD							
	Control group	Treated group	Control group	Treated group	Control group	Treated group	Control group	Treated group
1	3.0	0.0	5.0	0.0	4.0	0.0	2.0	0.0
2	4.0	0.0	4.0	0.0	3.0	0.0	1.0	0.0
3	6.0	0.0	5.0	0.0	4.0	0.0	0.5	0.0
4	3.0	2.0	3.0	0.0	2.0	0.0	1.0	0.0
5	5.0	2.0	3.0	0.0	3.0	0.0	0.5	0.0
6	3.0	0.0	4.0	0.0	5.0	0.0	2.0	0.0
7	3.0	0.0	5.0	0.0	4.0	0.0	1.0	0.0
8	5.0	1.0	5.0	0.0	1.0	0.0	0.5	0.0
9	3.0	3.0	3.0	0.0	2.0	0.0	1.0	0.0
10		0.0	5.0	0.0	2.0	0.0	0.5	0.0
Total	35	8.0	4.2	0.0	30	0.0	10	0.0
Mean	3.5	0.8	4.2	0.0	3.0	0.0	1.0	0.0

Efficacy		60%		100%		100%		100%
----------	--	-----	--	------	--	------	--	------

EXAMPLE VIII
MYCOBACTERIUM

Nitazoxanide was compared against izoniazide antibiotic. The protocol used BCG (Bacille de Calmette et Guerin) as a mycobacterium strain. The sensitivity of this strain was the same as that of *M. tuberculosis*, but this strain is more harmless and thus did not require high level of containment of a tuberculosis agent.

4 mg/mouse per day in 0.2 ml of sunflower oil was administered to mice. The results in mice treated with nitazoxanide were comparable to the group receiving izoniazide.

	10 ⁷			10 ⁵		
	Spleen	Liver	Lungs	Spleen	Liver	Lungs
Nitazo	1 575 000	1 575 000	57 500	68 250	70 000	50
	800 000	1 550 000	122 500	65 000	87 500	75
	875 000	1 550 000	30 000	75 000	35 000	150
	950 000	750 000	75 000	60 000	60 000	50
INH	475 000	1 050 000	11 000	20 000	21 250	50
	255 000	750 000	5 750	15 250	27 500	125
	200 000	975 000	4 000	60 000	52 500	50
				20 000	37 500	50
PBS	1 500 000	2 125 000	92 500	102 500	195 000	750
	1 525 000	1 800 000	98 000	140 000	175 000	800
	1 925 000	1 750 000	177 500	98 000	150 000	500
	1 675 000	1 800 000	117 500	105 000	150 000	750

EXAMPLE IX
FASCIOLA HEPATICA

The *in vitro* efficacy of nitazoxanide and desacetyl-nitazoxanide was tested against *Fasciola hepatica*.

Mature *F. hepatica* were recovered from the bile ducts of 3 calf livers condemned due to fasciolosis at the Louisiana Veterinary Medical Diagnostic Laboratory at the Hardy's Meat Packers, Bunkie, LA. Flukes were washed in sterile saline for 1 hour and transferred to sterile saline or RPMI (pH 7.4) for an additional 3 hours. Flukes were then held in sterile RPMI-rabbit serum (50:50 v/v) or sterile RPMI (pH 7.4) overnight at 37°C with 5% CO₂.

In vitro culture (37°C, 5% CO₂) was done according to a modification of the method of Ibarra and Jenkins (Z. Parasitenkd. 70:655-661, 1984). Using sterile technique, flukes were washed twice for 2-3 minutes in Hank's balanced salt solution (pH 7.2) and placed individually into wells of six-well Linbro culture plates containing 10 ml aliquots of the designated dilutions of the drug in culture media. The latter consisted of sterile 50:50 v/v RPMI-Rabbit serum with

2% Rabbit Blood plus 100 ppm Penicillin and 100 ppm Streptomycin. Only flukes that had normal activity and morphology were used.

Stock solutions of NTZ or its metabolite D-NTZ provided by Romark were dissolved in DMSO (2000 µg/ml) and diluted in culture medium, using 100 ml volumetric flasks, to produce the specified drug concentrations (100, 50, 25, 10, 5, 3, 1 µg/ml). Two control flukes were included in each replicate, one in unmediated culture media with RBC and one in unmedicated culture media with RBC.

Flukes were examined for the effects of drug treatment as evidenced by death, motility disturbances or morphologic changes as compared to untreated control flukes, using a backlighted panel and a lighted 3X magnifying lens.

Results:

Experiment 1: For D-NTZ, flukes in the 50 and 100 µg treatments were moribund or dead within one hour. Four of 7 flukes in the 25 µg treatment were moribund, two were active, and one was sluggish within the first hour; all were dead except two sluggish flukes by three hours and only one sluggish fluke remained alive after four hours. At 10 µg, reduced activity was noted at 1, 3 and 4 hours and all were moribund or dead by 7 hours. Reduced activity in some individuals was seen by 24 hours in the 5 µg and 3 µg groups with a somewhat slower onset at 3 µg; all were dead in the 3 and 5 µg treatment wells by 50 hours except one sluggish fluke in each group. Some slowing of activity was noted in the 1 µg group at 42-74 hours and only 3 active and one moribund fluke remained alive at 91 hours; at 115 hours only one sluggish fluke remained in the 1 µg group. Mortality in the control with RBC group was observed at 66 hours (one fluke), 91 hours (one fluke) and 115 hours (four flukes). In the Control without RBC group, all were alive at hour 91 and one was dead at hour 115.

Experiment 2: For NTZ, somewhat greater activity was noted by earlier effects on motility score and mortality in the 8 replicates as compared to results for D-NTZ. In the 100, 50 and 25 µg groups all flukes were dead or moribund except one fluke at 1 hour in the 25 µg group it was dead at 3 hour. Dose-related reduction in motility was seen in each of the other medicated groups beginning at hour 1. At 10 µg, only one fluke survived to 16 hours. In the 5 µg group, only 3 flukes were active at hour 6 and none were active at 16 hours. By 23 hours, only 2 sluggish flukes in the 3 µg group remained alive; these were dead by hour 41. For the 1

µg group, one fluke died by hour 16, three by hour 41 and five by hour 74; 3 flukes remained active at hour 91 and one fluke had activity at hour 115. In the Control with RBC group, 7 of 8 flukes were alive at hour 74, 3 were alive at hour 91 and 2 survived at hour 115. In the Control without RBC group, 6 of 8 flukes had activity at hour 74, 4 were active at hour 91 and two remained active at hour 115.

Fluke death in the high dose groups (25, 50, 100 µg) was rapid and associated with contraction and ventral 'curling'. At lower medication levels, most flukes slowed for a period and were more relaxed and 'flattened' when moribund or dead. Contamination became limiting on experimental results in some replicates beginning at hour 91. For the D-NTZ experiment, major bacterial or fungal overgrowth and associated mortality in two replicate plates occurred by hour 115. For the NTZ experiment, overgrowth and fluke mortality in entire replicate plates occurred by hour 91 (two replicates), and hour 115 (5 replicates). Hour 139 observations were not considered valid because of general contamination of most plates.

Conclusions:

Strong flukeicidal efficacy by nitazoxanide is suggested by experiments with both drugs tested. Somewhat greater flukeicidal activity against *F. hepatica* was observed for nitazoxanide than for desacetyl-nitazoxanide, the main metabolite, which is thought to be active at the hepatic level.

Rapid fluke death occurs within 1 hour at *in vitro* D-NTZ medication rates of >50 µg, within 4 hours at 25 µg and by 6-7 hours at 10µg. Ten µg, may be an appropriate single treatment target drug delivery rate if pharmacokinetic data indicate tissue levels are maintained for >6-8 hours after a single treatment.

Strong flukeicidal activity by 74 hours (three days) was observed for both compounds at the 3 and 5 µg dose rates. Prolonged survival approaching, but not equal to unmedicated control flukes was observed at the 1µg dose level; delivery of this level of drug to flukes in hepatic tissues for 3 to 4 days may therefore have inadequate therapeutic effect on parasites.

EXAMPLE X

FASCIOLA GIGANTICA

Nitazoxanide was tested against immature and mature *Fasciola gigantica* in experimentally infected rabbits.

Fasciola gigantica encysted metacercariae (EMC) were collected on cellophane sheet after 28-35 days from infection of *L. calludi* snails by *Fasciola gigantica* miracidium using the technique described by Abdel-Ghany where snails were exposed daily to artificial light, for 30

minutes, in clean dechlorinated tap water. The resulting encysted metacercariae (EMC) were preserved at 4°C in a refrigerator for 5 to 8 days under the surface of water until they were used to infect experimental animals.

Forty (40) Boscat rabbits, weighting 1.5 to 2 kg each, were included in the study and allocated to two treatment groups of 20 animals.

Animals from Group 1 were orally infected with 35-40 encysted metacercariae wrapped in a leaf of lettuce and pushed on the root of the tongue of the animals. The mouths of the animals were held closed by hand until the encysted metacercariae were swallowed. These Group 1 animals were used to test the efficacy of nitazoxanide against immature stages (4-5 weeks old) of *Fasciola gigantica*.

Animals from Group 2 were orally infected as indicated above with 10-15 encysted metacercariae and were used to test the efficacy of nitazoxanide against the early mature flukes (>10 weeks old).

Ten animals from Group 1 received 35 mg of nitazoxanide, morning and evening, for 7 consecutive days 4 weeks after their infection at the immature stage of the parasite cycle. The ten remaining animals in Group 1 were kept as untreated controls.

Ten animals from Group 2 received 35 mg of nitazoxanide, morning and evening, for 7 consecutive days 10 weeks after their infection at the mature stage of the parasite. The 10 remaining animals in Group 2 were kept as untreated controls.

All animals were fed with dry ration until the end of the experiment.

Seven days after administration of the last dose of nitazoxanide, all rabbits from each group were sacrificed. The surface of the liver was examined for the presence of necrotic migrating furrows especially at the immature stage of the parasite cycle. These necrotic areas were examined using two surgical needles in order to extract the juvenile migrating flukes according to the technique described by El-Bahy. The livers were sliced in small pieces especially around the migrating furrows and macerated under a microscope in order to extract the existing flukes. The abdominal cavity and the visceral surfaces were washed with warm water. The water was then collected, sieved and examined for identification of juvenile flukes. All the collected parasites as well as parts of them were counted in both treated and untreated animal in both Groups 1 and 2. Living flukes appeared pin in color, translucent showing intact teguments, easily extractable from the tissue of the livers using warm water, while dead flukes were grayish in color loose and showed a broken necrotic surface. The efficacy of nitazoxanide was calculated by using the formula indicated below:

$$\% \text{ efficacy} = \frac{a - b}{a} \times 100$$

Where: a = the number of flukes recovered from feces in the control animals

b = the number of flukes recovered from feces in the treated animals.

Results

The results of the study as indicated in Table 7 show a marked decrease in the number of immature flukes recovered from the liver of rabbits in the treated group when compared in the control group. The means percentage of reduction was calculated as 46.77% (range: 40-60%).

Table 7: Efficacy of nitazoxanide against immature (4-week/old) *F. gigantica* in experimentally infected rabbits

No. of flukes extracted from liver of			
Rabbit No.	Untreated Control	Treated Rabbits	Efficacy %
1	7	4	42%
2	7	4	42%
3	6	3	50%
4	8	4	50%
5	5	3	40%
6	5	2	60%
7	5	3	40%
8	6	3	50%
9	8	4	50%
10	5	3	40%
Mean	6.2	3.3	46.77%

At the early mature stage of their infection, nitazoxanide showed a complete effect (100% reduction) and no worms could be seen after examination of the liver of the treated rabbits in comparison with the untreated control animals as shown in Table 8.

Table 8: Efficacy of nitazoxanide against early mature (10-week/old) *F. gigantica* in experimentally infected rabbits

No. of flukes extracted from liver of			
Rabbit No.	Untreated Control	Treated Rabbits	Efficacy %
1	4	0.0	100%
2	4	0.0	100%
3	3	0.0	100%
4	3	0.0	100%
5	2	0.0	100%
6	2	0.0	100%
7	2	0.0	100%
8	3	0.0	100%
9	3	0.0	100%
10	3	0.0	100%
Mean	2.9	0.0	100%

Nitazoxanide administered as a 70 mg/day dose for 7 consecutive days is moderately effective against immature stage of *Fasciola gigantica* and completely effective against the early mature stage of the parasite.

EXAMPLE XIII *SCHISTOSOMA*

9	22	8
10	30	7
Total	247	99
Mean/Mouse	24.7	9.9
Efficacy		59.91


Table 10: Efficacy of nitazoxanide against mature (13-week/old) *Schistosoma hematobium* in mice

No. of flukes removed from liver of		
Mice No.	Untreated Control	Treated Mice
1	18	3
2	16	3
3	14	2
4	19	2
5	12	4
6	10	4
7	13	2
8	12	2
9	17	0.0
10	9	2
Total	140	24
Mean/Mouse	14	2.4
Efficacy		82.85


WHAT I CLAIM IS

1. A pharmaceutical composition for oral administration containing as active agent at least one compound selected from the group consisting of:

compound of formula (I)



and compound of formula (II)



2. The composition of claim 1, wherein said active compound is in the form of active particles having a particle size smaller than 200 μm and a mean particle size of greater than 10 μm .

3. The composition of claim 2, wherein the mean particle size of said active particles is between 10 and 100 μm .

4. The composition of claim 2, wherein the mean particle size of said active particles is between 20 and 50 μm .

5. The composition of claim 2, wherein less than 10% by weight of said active particles has a particle size larger than 100 μm .

6. The composition of claim 2, wherein at least 50% by weight of said active particles has a particle size smaller than 50 μm .

7. The composition of claim 2, wherein less than 10% by weight of said active particles has a particle size smaller than 5 μm .

8. The composition of claim 2, said composition comprising a mixture of active particles of compounds of formula (I) and of formula (II), the weight content of compound of formula (I) with respect to the weight of compounds of formula (I) and of formula (II) of said mixture being comprised between 0.5 and 20%.


9. The composition of claim 1, wherein said composition further contains at least one pharmaceutically acceptable acid.

10. The composition of claim 9, wherein said pharmaceutically acceptable acid is selected from the group consisting of citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartaric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof.


11. The composition of claim 9, wherein said active agent is in the form of solid particles having a particle size smaller than 200 μm and a mean particle size of greater than 10 μm , and wherein the ratio of the weight of pharmaceutically acceptable acid/the weight of said solid particles is between 0.01 and 0.5.

12. The composition of claim 11, wherein the ratio of the weight of pharmaceutically acceptable acid/the weight of said active solid particles is between 0.03 and 0.2.

13. Use of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula (I):



and a compound of formula (II):



for manufacture of a medicament for treating an infection in an immunocompromised mammal by a microorganism selected from the group consisting of *Cryptosporidium parvum*, *Isospora belli*,

Enterocytozoon bieneusi, *Encephalitozoon intestinalis*, *Mycobacterium tuberculosis*, *Mycobacterium avium intracellulare*, *Pneumocystis carinii*, and *Toxoplasma gondii*.

14. Use of a pharmaceutical composition as in claim 13, wherein said active agent is in the form of particles with a mean particle size of between 10 and 200 μm .

15. Use of a pharmaceutical composition as in claim 13, wherein said active agent is in the form of particles with a mean particle size of between 20 and 50 μm .

16. Use of a pharmaceutical composition as in claim 13, wherein said pharmaceutical composition contains at least one pharmaceutically acceptable acid.

17. Use of a pharmaceutical composition as in claim 16, wherein said pharmaceutically acceptable acid is selected from the group consisting of citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartaric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof.


18. Use of a pharmaceutical composition as in claim 13, wherein said active agent is a compound of formula (I).

19. Use of a pharmaceutical composition as in claim 13, wherein said active agent is a compound of formula (II).


20. Use of a pharmaceutical composition as in claim 13, wherein said mammal is human and wherein said active agent is administered in an amount of from 500- 2000 mg daily.

21. Use of a pharmaceutical composition as in claim 20, wherein said active agent is administered in an amount of from 1000- 1500 mg daily.

22. Use of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I:




and a compound of formula II:




for manufacture of a medicament for treating a parasitic infection by a trematode selected from the group consisting of *Schistosoma Fasciola*, *Fasciolopsis*, *Dicrocoelium*, *Heterophyes*, and *Metagonimus*.

23. Use of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I:



and a compound of formula II:



for manufacture of a medicament for treating a parasitic infection of a trematode selected from the group consisting of *Schistosoma mansoni*, *Schistosoma haematobium*, *Schistosoma mekongi*, *Schistosoma japonicum*, *Schistosoma intercalatum*, *Fasciola hepatica*, *Fasciola gigantica*, *Fasciolopsis biski*, *Dicrocoelium dendriticum*, *Heterophyes heterophyes*, and *Metagonimus yokogawa*.

24. Use of a pharmaceutical composition as in claim 23, wherein said active agent is in the form of particles with a mean particle size of between 10 and 200 μm .

25. Use of a pharmaceutical composition as in claim 24, wherein said active agent is in the form of particles with a mean particle size of between 20 and 50 μm .

26. Use of a pharmaceutical composition as in claim 23, wherein said pharmaceutical composition contains at least one pharmaceutically acceptable acid.


27. Use of a pharmaceutical composition as in claim 26, wherein said pharmaceutically acceptable acid is selected from the group consisting of citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartaric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof.

28. Use of a pharmaceutical composition as in claim 26, wherein the ratio of the weight of pharmaceutically acceptable acid/the weight of said active particles is between 0.01 and 0.5.


29. Use of a pharmaceutical composition as in claim 23, wherein said active agent is a compound of formula (I).

30. Use of a pharmaceutical composition as in claim 23, wherein said active agent is a compound of formula (II).

31. A pharmaceutical paste for topical administration, said paste comprising:
 as active agent, solid particles of at least one compound selected from the group consisting of:
 compound of formula (I)



and compound of formula (II)



said particles having a particle size smaller than 200 μm and a mean particle size greater than 10 μm ;

at least one thickener;

at least one wetting agent; and


at least one pharmaceutically acceptable acid, the pH of the paste being between 2 and 6.

32. A pharmaceutical paste as in claim 31, wherein said paste further comprises at least one additive selected from the group consisting of cetylic alcohol, glyceride derivatives, proylene glycol, and mixtures thereof.


33. A pharmaceutical composition for oral administration containing active agent granulated in the presence of a granulating agent, wherein:

- said active agent is in the form of solid active particles of at least one compound selected from the group consisting of:

compound of formula (I)



compound of formula (II)



and wherein said active particles have a particle size smaller than 200 μm and a mean particle size of greater than 10 μm .

34. The composition of claim 33, wherein said granulating agent is selected from the group consisting of polyvinylpyrrolidone, water, alcohol, sucrose, hydroxyl cellulose and mixture thereof.

35. The composition of claim 33, wherein said granulated active solid particles contain at least one pharmaceutically acceptable acid.


36. The composition of claim 35, wherein said pharmaceutically acceptable acid is selected from the group consisting of citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartaric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof.

37. The composition of claim 35, wherein the ratio of the weight of pharmaceutically acceptable acid/the weight of said active agent is between 0.01 and 0.5.


38. A pharmaceutical composition for oral administration containing active agent, a wetting agent and a starch derivative, wherein:

- said active agent is in the form of solid active particles of at least one compound selected from the group consisting of:

compound of formula (I)



compound of formula (II)



and wherein said active particles having a particle size smaller than $200\ \mu\text{m}$ and a mean particle size of greater than $10\ \mu\text{m}$.


39. The pharmaceutical composition of claim 38, further comprising at least one pharmaceutically acceptable acid.

40. The pharmaceutical composition of claim 38, wherein the active particles are granulated in the presence of a granulating agent to form granulated active agent containing from 2 to 99.97% by weight of said active compound and from 0.03 to 10% by weight of a granulating agent.


41. The pharmaceutical composition of claim 40, wherein said granulating agent is selected among the group consisting of polyvinylpyrrolidone, water, alcohol, sucrose, hydroxyl cellulose and mixtures thereof.

42. A liquid suspension of active agent for oral administration, said suspension containing:

- as active agent, solid particles of at least one compound selected from the group consisting of:
compound of formula (I)



and compound of formula (II)



said particles having a particle size smaller than 200 μm and a mean particle size greater than 10 μm ; and


- at least one pharmaceutically acceptable acid, the pH of the suspension being between 2 and 6.

43. The suspension of claim 42, wherein the pH of the suspension is between 3 and 5.


44. The suspension of claim 42, further comprising a granulating agent.

ABSTRACT OF THE DISCLOSURE

A pharmaceutical composition containing as active agent at least one compound selected among the group consisting of formula (I)



and formula (II)



The active agent is preferably in the form of particles having a particle size smaller than 200 μm and a mean particle size of greater than 10 μm . The pharmaceutical compositions are preferably stabilized with at least one pharmaceutically acceptable acid. The pharmaceutical compositions are particularly useful for treatment of opportunistic infections in persons with compromised or suppressed immune systems, and in treatment of infections of trematodes.